

## BioCLIA Autoimmune Control Set, gp210

Cat.No.	Kit Size
MY00318	2 X 1 mL
MY00369	4 X 1 mL

### INTENDED USE

The BioCLIA Autoimmune Control Set, gp210 is intended for the quality control purposes of the BioCLIA gp210 performed on the BioCLIA 6500 and BioCLIA 500. For professional *in vitro* diagnostic use only.

### SUMMARY AND EXPLANATION

Autoimmune liver diseases (ALD) include autoimmune hepatitis (AIH),<sup>1, 2</sup> primary biliary cirrhosis (PBC)<sup>3</sup> and primary sclerosing cholangitis (PSC).<sup>4</sup> Determination of indicators such as AMA, CENP-B, LKM-1 and SLA/LP has significant correlation to ALD diagnosis.

Anti-gp210 antibodies can specifically bind to a 210 kDa transmembrane glycoprotein on the nuclear pore complex in the 15 amino acid residues of gp210 carboxyl terminal. Anti-gp210 antibody detection has important value for PBC diagnosis for the patients with suspected clinical, biochemical and histologic findings but anti-mitochondrial antibodies (AMAs) negative, or the ones with AMAs positive but not typical in clinical syndromes. It is present approximately 25%~30% in PBC patients.<sup>5, 6, 7, 8</sup>

### MATERIALS SUPPLIED

- **gp210 Control N** Barcode labeled tubes with buffer containing human antibodies to gp210 in stabilizers and preservatives. Ready to use, 1 mL.

Control	N
---------	---

Preservatives: 0.0015% < Proclin 300 < 0.6%.

- **gp210 Control P** Barcode labeled tubes with buffer containing human antibodies to gp210 in stabilizers and preservatives. Ready to use, 1 mL.

Control	P
---------	---

Preservatives: 0.0015% < Proclin 300 < 0.6%.

The Control Code contains controls' information is provided in each kit.

Target value and acceptance range for the controls are indicated on the card provided in each kit.

### WARNINGS AND PRECAUTIONS

- For professional *in vitro* diagnostic use only.
- Do not use any controls beyond their expiration dates.
- Do not mix controls from different lots unless specified.
- Instructions must be carefully followed for using and storing of controls. Any modification in procedure may interfere with the results.
- Controls and contaminated vials must be handled strictly

following safety guidelines or rules of biological hazards to ensure the users' and environmental safety.

- Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established!

### Precautions:



Human serum is added in the controls.

- The human derived material in this product was tested by FDA approved methods and found nonreactive for Hepatitis B Surface Antigen (HBsAg), Anti-HCV and HIV 1/2 antibodies. Handle as if potentially infectious. 7 Avoid contacting with skin and eyes. Do not empty into drains. Wear suitable protective clothing.



- Proclin 300 is added in the controls at concentration between 0.0015% - 0.6%.
- Controls contain chemical and biological components. Avoid ingesting or splashing onto skin and mucous membrane. If direct contact with controls happens, rinse the contact surface with plenty of water immediately and see a doctor if necessary.

### STORAGE CONDITIONS

- Store the kit at 2-8 °C.
- The shelf life of the unopened kit is 12 months from day of production.
- Vial opened controls could be used for 28 successive days, exposure no more than 2 hours each time when kept uncapped and is good for up to 35 controls, after which the reagent must be discarded.
- Avoid repeated freezing and thawing.

### ASSAY PROCEDURE

Detailed information about operating the BioCLIA instruments can be taken from the Instrument User's Manual.

Note that, it is important to perform all routine maintenance procedures for optimal performance.

### Control

The control procedure should be done before running the specimens each day. Users also can adjust the control procedure period according to their own lab frequency.

Each Laboratory should establish its own reference ranges.

### Programming and Running samples

1. Put the kit into the corresponding position of the reagent chamber of the fully automatic chemiluminescence analyzer. The information of the kit can be uploaded into the instrument system through the scanning of reagent barcode, and can also be set through the supporting software of the instrument.
2. The information of calibrator / quality control is identified by scanning the calibrator / control barcodes, and the position of calibrator / quality control is assigned in the instrument system.
3. The sample to be tested is placed on the instrument sample rack chamber, and the corresponding test information is edited through the instrument supporting software.
4. Start the operation procedure, and all calibrator / quality control / sample processing steps will be automatically executed.

### TRACEABILITY

The reported values were determined over multiple runs on the BioCLIA 6500 and BioCLIA 500 using specific lots of reagents against an in-house standard. DGP IgA results are reported in RU/mL which is interpreted from relative light unit (RLU). Method comparison test showed good sensitivity and specificity of tested assay.

### LIMITATIONS

- The controls are designed for control of the same lot of BioCLIA Autoimmune Reagent Kit.
- The controls can be kept uncapped onboard the instrument up to 2 hours for each time of usage. And a total up to 35 controls are suggested, for any longer period of time, the reagent should be discarded, otherwise may result in improper results.

### SYMBOLS

	Catalog Number		Use-by date
	In Vitro diagnostic medical device		Lot Number
	Store between +2°C and +8°C		Consult Instruction for Use
	Manufacturer		Authorized Representative in the European Community
	CE Marking		Contains Sufficient for <n> Tests
	Biological Risk		GHS07 Warning

	Negative Control
	Positive Control

### REFERENCE

1. Czaja AJ. Autoimmune liver disease. Current Opinion in Gastroenterology 2007;23:255-62.
2. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli - Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-213.
3. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti - gp210 and anti - centromere antibodies are different risk factors for the

progression of primary biliary cirrhosis. Hepatology 2007;45:118-27.

4. T Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert review of gastroenterology & hepatology 2013;7:103-14.
5. ITOH S, ICHIDA T, YOSHIDA T, HAYAKAWA A, UCHIDA M, TASHIRO - ITOH T, et al. Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. Journal of gastroenterology and hepatology 1998;13:257-65.
6. Nakamura M, Shimizu-Yoshida Y, Takii Y, Komori A, Yokoyama T, Ueki T, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. Journal of hepatology 2005;42:386-92.
7. Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, Shimizu-Yoshida Y, et al. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. Journal of autoimmunity 2006;26:138-45
8. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti - gp210 and anti - centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-27.
9. Richmond JY, Mckinney RW. Biosafety in microbiological and biomedical laboratories: U.S.GPO. 1999.



**HOB Biotech Group Corp., Ltd.**  
C6 Building, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, 215123, China

### CONTACT INFORMATION:

TEL (+86)512-69561996

Fax (+86)512-62956652

WEBSITE: [www.hob-biotech.com](http://www.hob-biotech.com)

CUSTOMER SERVICE: HOB Biotech Group Co., Ltd

CUSTOMER SERVICE: TEL (+86)4008601202



EUROPE REPRESENTATIVE: Emergo Europe

### ADDRESS/LOCATION:

Prinsessegracht 20, 2514 AP The Hague, The Netherlands



The eIFU is available on Website:

<http://en.hob-biotech.com/usercenter/login.aspx>

### TECHNICAL ASSISTANCE

For technical assistance, contact your National Distributor.

Date of issue: 17<sup>th</sup> March 2019

Date of revision: 20<sup>th</sup> December 2021

Change Control Number: CN21129E

Version: A/1 (EN)